Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|May 31, 2015
IPEC-Americas Seeks Award Applications
Author(s)Pharmaceutical Technology Editors
The IPEC-Americas Foundation is accepting applications for graduate student, research, and industry research achievement awards.
Advertisement
The IPEC-Americas Foundation is accepting applications for the 2015 awards, including five graduate student travel scholarships to attend the AAPS 2015 Annual Meeting in Orlando, Florida October 25-29.
Awards are given in three categories. The Ralph Shangraw Memorial Award of $10,000 given to any person who has provided outstanding research contributions in the study of excipients or excipient-related technology over a number of years. The award is open to all scientists of any nationality or residence working in this field of research.
The Industry Research Achievement Award recognizes individuals working in an industrial setting who have made significant contributions in the field of excipient technology.
In addition, five graduate student scholarships of $1,500 are awarded to acknowledge excellence in research conducted at the graduate level in the field of excipients. Students with recent significant contributions to formulation science and technology through innovative research with excipients are eligible for this award.
Proposed award recipients may be nominated by professors, counselors, or faculty members at institutions of higher learning; members of the Foundation; and employees in the pharmaceutical, chemical, food, or excipient industry.
Applications can be found on the
Source:
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
Complying with International Pharmacopoeias
5